BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: De Laurentiis M, Cancello G, D’Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44-53. [PMID: 18165639 DOI: 10.1200/jco.2007.11.3787] [Cited by in Crossref: 284] [Cited by in F6Publishing: 85] [Article Influence: 21.8] [Reference Citation Analysis]
Number Citing Articles
1 Jacquemier J, Boher JM, Roche H, Esterni B, Serin D, Kerbrat P, Andre F, Finetti P, Charafe-Jauffret E, Martin AL, Campone M, Viens P, Birnbaum D, Penault-Llorca F, Bertucci F. Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res 2011;13:R109. [PMID: 22044691 DOI: 10.1186/bcr3051] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
2 Han HH, Lee SH, Kim BG, Lee JH, Kang S, Cho NH. Estrogen Receptor Status Predicts Late-Onset Skeletal Recurrence in Breast Cancer Patients. Medicine (Baltimore) 2016;95:e2909. [PMID: 26937933 DOI: 10.1097/MD.0000000000002909] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
3 Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL. Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts. Breast Cancer Res 2011;13:R85. [PMID: 21888627 DOI: 10.1186/bcr2937] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
4 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 64] [Article Influence: 10.3] [Reference Citation Analysis]
5 Katsuta E, Yan L, Nagahashi M, Raza A, Sturgill JL, Lyon DE, Rashid OM, Hait NC, Takabe K. Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer. J Surg Res 2017;219:202-13. [PMID: 29078883 DOI: 10.1016/j.jss.2017.05.101] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
6 Holmes FA, Hellerstedt BA, Pippen JE Jr, Vukelja SJ, Collea RP, Kocs DM, Blum JL, McIntyre KJ, Barve MA, Brooks BD, Osborne CR, Wang Y, Asmar L, O'Shaughnessy J. Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer. Cancer Med 2018;7:2288-98. [PMID: 29582557 DOI: 10.1002/cam4.1472] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Garcia-Chagollan M, Carranza-Torres IE, Carranza-Rosales P, Guzmán-Delgado NE, Ramírez-Montoya H, Martínez-Silva MG, Mariscal-Ramirez I, Barrón-Gallardo CA, Pereira-Suárez AL, Aguilar-Lemarroy A, Jave-Suárez LF. Expression of NK Cell Surface Receptors in Breast Cancer Tissue as Predictors of Resistance to Antineoplastic Treatment. Technol Cancer Res Treat 2018;17:1533033818764499. [PMID: 29558872 DOI: 10.1177/1533033818764499] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
8 Xu B, Shao Z, Wang S, Jiang Z, Hu X, Zhang X, Li X, Liu J, Li M, Wang S. Treatment patterns for adjuvant docetaxel-based chemotherapy in early-stage breast cancer in China: A pooled retrospective analysis of four observational studies. Chin J Cancer Res 2018;30:327-39. [PMID: 30046227 DOI: 10.21147/j.issn.1000-9604.2018.03.05] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Vianna-Jorge R, Festa-Vasconcellos JS, Goulart-Citrangulo SM, Leite MS. Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer. Front Genet 2012;3:329. [PMID: 23346096 DOI: 10.3389/fgene.2012.00329] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
10 Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol 2014;5:283-98. [PMID: 25114845 DOI: 10.5306/wjco.v5.i3.283] [Cited by in CrossRef: 103] [Cited by in F6Publishing: 64] [Article Influence: 14.7] [Reference Citation Analysis]
11 Moreno-Aspitia A, Perez EA. Treatment options for breast cancer resistant to anthracycline and taxane. Mayo Clin Proc 2009;84:533-45. [PMID: 19483170 DOI: 10.1016/S0025-6196(11)60585-5] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
12 Swaroop MN, Ferguson CM, Horick NK, Skolny MN, Miller CL, Jammallo LS, Brunelle CL, O'Toole JA, Isakoff SJ, Specht MC, Taghian AG. Impact of adjuvant taxane-based chemotherapy on development of breast cancer-related lymphedema: results from a large prospective cohort. Breast Cancer Res Treat 2015;151:393-403. [PMID: 25940996 DOI: 10.1007/s10549-015-3408-1] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 5.3] [Reference Citation Analysis]
13 Feng QJ, Zhang F, Huang XY, Wu ZX. Effectiveness and complications of anthracycline and taxane in the therapy of breast cancer: a meta-analysis. Pathol Oncol Res 2014;20:179-84. [PMID: 23980023 DOI: 10.1007/s12253-013-9681-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
14 Gao M, Zhang D, Jin Q, Jiang C, Wang C, Li J, Peng F, Huang D, Zhang J, Song S. Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model. Oncotarget 2016;7:58133-41. [PMID: 27531898 DOI: 10.18632/oncotarget.11249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
15 Paula DP, do Brasil Costa VI, Jorge RV, Nobre FF. Impact of protocol change on individual factors related to course of adverse reactions to chemotherapy for breast cancer. Support Care Cancer 2020;28:395-403. [PMID: 31056713 DOI: 10.1007/s00520-019-04841-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Clavarezza M, Mustacchi G, Casadei Gardini A, Del Mastro L, De Matteis A, Riccardi F, Adamo V, Aitini E, Amoroso D, Marchetti P, Gori S, Carrozza F, Maiello E, Giotta F, Dondi D, Venturini M. Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study. BMC Cancer 2012;12:216. [PMID: 22672524 DOI: 10.1186/1471-2407-12-216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
17 Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, Jeong JH, Wolmark N, Kidwell K, Paik S, Swain SM. Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol 2010;28:2974-81. [PMID: 20479407 DOI: 10.1200/JCO.2009.26.1602] [Cited by in Crossref: 39] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
18 Camerini A, Donati S, Viacava P, Siclari O, Puccetti C, Tartarelli G, Valsuani C, De Luca F, Martini L, Cavazzana A, Amoroso D. Evaluation of HER2 and p53 expression in predicting response to docetaxel-based first-line chemotherapy in advanced breast cancer. J Exp Clin Cancer Res 2011;30:38. [PMID: 21481270 DOI: 10.1186/1756-9966-30-38] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
19 Zhang JF, Liu J, Wang Y, Zhang B. Novel therapeutic strategies for patients with triple-negative breast cancer. Onco Targets Ther. 2016;9:6519-6528. [PMID: 27799799 DOI: 10.2147/ott.s105716] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
20 Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol 2015;1:1311-8. [PMID: 26402167 DOI: 10.1001/jamaoncol.2015.3062] [Cited by in Crossref: 41] [Cited by in F6Publishing: 31] [Article Influence: 8.2] [Reference Citation Analysis]
21 Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update. 2009;15:323-339. [PMID: 19174449 DOI: 10.1093/humupd/dmn064] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 7.1] [Reference Citation Analysis]
22 Brown JC, Winters-Stone K, Lee A, Schmitz KH. Cancer, physical activity, and exercise. Compr Physiol. 2012;2:2775-2809. [PMID: 23720265 DOI: 10.1002/cphy.c120005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 73] [Article Influence: 5.5] [Reference Citation Analysis]
23 Hirai I, Tanese K, Nakamura Y, Ishii M, Kawakami Y, Funakoshi T. Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease. Oncologist 2019;24:e394-6. [PMID: 30846514 DOI: 10.1634/theoncologist.2018-0856] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
24 Möbus V, Hell S, Schmidt M. Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer. Geburtshilfe Frauenheilkd 2017;77:1079-87. [PMID: 29093601 DOI: 10.1055/s-0043-119542] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Kang YK, Si YR, An GY, Yuan P. Efficacy and safety of cyclophosphamide in anthracycline- and taxane-based neoadjuvant chemotherapy in breast cancer: a meta-analysis. Gland Surg 2021;10:252-61. [PMID: 33633981 DOI: 10.21037/gs-20-593] [Reference Citation Analysis]
26 Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008;26:4092-9. [PMID: 18678836 DOI: 10.1200/JCO.2008.16.7841] [Cited by in Crossref: 74] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
27 Xue C, Wang X, Peng R, Shi Y, Qin T, Liu D, Teng X, Wang S, Zhang L, Yuan Z. Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci 2012;103:1679-87. [PMID: 22625227 DOI: 10.1111/j.1349-7006.2012.02339.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
28 Bonnefoi H, Piccart M, Bogaerts J, Mauriac L, Fumoleau P, Brain E, Petit T, Rouanet P, Jassem J, Blot E, Zaman K, Cufer T, Lortholary A, Lidbrink E, André S, Litière S, Lago LD, Becette V, Cameron DA, Bergh J, Iggo R; EORTC 10994/BIG 1-00 Study Investigators. TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial. Lancet Oncol 2011;12:527-39. [PMID: 21570352 DOI: 10.1016/S1470-2045(11)70094-8] [Cited by in Crossref: 93] [Cited by in F6Publishing: 39] [Article Influence: 9.3] [Reference Citation Analysis]
29 Guarneri V, Dieci MV, Conte P. Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs 2013;73:1257-65. [PMID: 23842749 DOI: 10.1007/s40265-013-0091-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
30 Zhi WI, Chen P, Kwon A, Chen C, Harte SE, Piulson L, Li S, Patil S, Mao JJ, Bao T. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing. Breast Cancer Res Treat 2019;178:587-95. [PMID: 31456070 DOI: 10.1007/s10549-019-05416-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
31 Saito Y, Takekuma Y, Kobayashi M, Sakamoto T, Yamashita H, Sugawara M. Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis. Support Care Cancer 2021. [PMID: 34228171 DOI: 10.1007/s00520-021-06342-2] [Reference Citation Analysis]
32 Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V. Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br J Cancer 2013;108:549-56. [PMID: 23329233 DOI: 10.1038/bjc.2012.597] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
33 Martín M, Prat A, Rodríguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, Rodríguez CA, López-Vega JM, Furió V, García AM, Casas M, Ellis MJ, Berry DA, Pitcher BN, Harris L, Ruiz A, Winer E, Hudis C, Stijleman IJ, Tuck DP, Carrasco E, Perou CM, Bernard PS. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat 2013;138:457-66. [PMID: 23423445 DOI: 10.1007/s10549-013-2416-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
34 O'Shaughnessy JA, Kaufmann M, Siedentopf F, Dalivoust P, Debled M, Robert NJ, Harbeck N. Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist 2012;17:476-84. [PMID: 22418569 DOI: 10.1634/theoncologist.2011-0281] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
35 Cardonick E. Pregnancy-associated breast cancer: optimal treatment options. Int J Womens Health. 2014;6:935-943. [PMID: 25395871 DOI: 10.2147/ijwh.s52381] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
36 He J, Fortunati E, Liu DX, Li Y. Pleiotropic Roles of ABC Transporters in Breast Cancer. Int J Mol Sci 2021;22:3199. [PMID: 33801148 DOI: 10.3390/ijms22063199] [Reference Citation Analysis]
37 Morris PG, Hudis CA. Optimizing dose-dense regimens for early-stage breast cancer. Nat Rev Clin Oncol 2010;7:678-9. [PMID: 21116238 DOI: 10.1038/nrclinonc.2010.188] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
38 Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L. Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis. Breast Cancer Res Treat 2019;173:1-9. [PMID: 30242579 DOI: 10.1007/s10549-018-4969-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
39 Ntellas P, Spathas N, Agelaki S, Zintzaras E, Saloustros E. Taxane & cyclophosphamide vs anthracycline & taxane-based chemotherapy as adjuvant treatment for breast cancer: a pooled analysis of randomized controlled trials by the Hellenic Academy of Oncology. Oncotarget 2019;10:1209-16. [PMID: 30838092 DOI: 10.18632/oncotarget.26632] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
40 Pérez-Fidalgo JA, Bermejo B, Chirivella I, Martínez MT, González I, Cejalvo JM, Catoira I, Martínez P, Contel E, Lluch A. Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer. Clin Transl Oncol 2014;16:814-22. [PMID: 24532305 DOI: 10.1007/s12094-013-1153-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
41 Liang C, Li L, Fraser CD, Ko A, Corzo D, Enger C, Patt D. The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. BMC Cancer 2015;15:1019. [PMID: 26714468 DOI: 10.1186/s12885-015-2027-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
42 Fitzpatrick A, Tutt A. Controversial issues in the neoadjuvant treatment of triple-negative breast cancer. Ther Adv Med Oncol 2019;11:1758835919882581. [PMID: 31700549 DOI: 10.1177/1758835919882581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
43 Kim YJ, Park W, Ha B, Park B, Joo J, Kim TH, Park IH, Lee KS, Lee ES, Shin KH, Kim H, Yu JI, Choi DH, Huh SJ, Wee CW, Kim K, Park KR, Kim YB, Ahn SJ, Lee JH, Kim JH, Chun M, Lee HS, Kim JS, Cha J. Postmastectomy Radiotherapy in Patients with pT1-2N1 Breast Cancer Treated with Taxane-Based Chemotherapy: A Retrospective Multicenter Analysis (KROG 1418). Cancer Res Treat 2017;49:927-36. [PMID: 28052654 DOI: 10.4143/crt.2016.508] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
44 Vandenberg T, Younus J, Al-Khayyat S. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis. Curr Oncol 2010;17:2-3. [PMID: 20404969 DOI: 10.3747/co.v17i2.498] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
45 Livi L, Meattini I, Scotti V, Saieva C, Simontacchi G, Marrazzo L, Franzese C, Cassani S, Paiar F, Di Cataldo V, Nori J, Jose Sanchez L, Bianchi S, Cataliotti L, Biti G. Concomitant adjuvant chemo-radiation therapy with anthracycline-based regimens in breast cancer: a single centre experience. Radiol Med 2011;116:1050-8. [PMID: 21424317 DOI: 10.1007/s11547-011-0652-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
46 Dang C, Iyengar N, Datko F, D'Andrea G, Theodoulou M, Dickler M, Goldfarb S, Lake D, Fasano J, Fornier M, Gilewski T, Modi S, Gajria D, Moynahan ME, Hamilton N, Patil S, Jochelson M, Norton L, Baselga J, Hudis C. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2015;33:442-7. [PMID: 25547504 DOI: 10.1200/JCO.2014.57.1745] [Cited by in Crossref: 51] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
47 Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth KS, Quinaux E, Buyse M, Dolci MS, Azambuja ED, Hainaut P, Dell'orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Leo AD, Olivier M. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 2012;14:R70. [PMID: 22551440 DOI: 10.1186/bcr3179] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
48 Vishnu P, Roy V. Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer. Breast Cancer (Auckl) 2011;5:53-65. [PMID: 21603258 DOI: 10.4137/BCBCR.S5857] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
49 Muñoz E, González N, Muñoz L, Aguilar J, Velasco JA. Ovarian stimulation in patients with breast cancer. Ecancermedicalscience 2015;9:504. [PMID: 25729417 DOI: 10.3332/ecancer.2015.504] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
50 Chen Y, Shi XE, Tian JH, Yang XJ, Wang YF, Yang KH. Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis. Medicine (Baltimore) 2018;97:e10634. [PMID: 29768327 DOI: 10.1097/MD.0000000000010634] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
51 Liu Y, Fang J, Joo KI, Wong MK, Wang P. Codelivery of chemotherapeutics via crosslinked multilamellar liposomal vesicles to overcome multidrug resistance in tumor. PLoS One 2014;9:e110611. [PMID: 25330237 DOI: 10.1371/journal.pone.0110611] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
52 Thu KL, Soria-Bretones I, Mak TW, Cescon DW. Targeting the cell cycle in breast cancer: towards the next phase. Cell Cycle 2018;17:1871-85. [PMID: 30078354 DOI: 10.1080/15384101.2018.1502567] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
53 Coudert B, Asselain B, Campone M, Spielmann M, Machiels JP, Pénault-Llorca F, Serin D, Lévy C, Romieu G, Canon JL, Orfeuvre H, Piot G, Petit T, Jerusalem G, Audhuy B, Veyret C, Beauduin M, Eymard JC, Martin AL, Roché H; UNICANCER Breast Group. Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial. Oncologist 2012;17:900-9. [PMID: 22610153 DOI: 10.1634/theoncologist.2011-0442] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
54 Manchon P, Borràs JM, Ferro T, Espinàs JA; Breast Cancer OncoGuia Group. Breast Cancer OncoGuia. Clin Transl Oncol 2010;12:113-38. [PMID: 20156781 DOI: 10.1007/s12094-010-0477-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
55 Hansen SN, Ehlers NS, Zhu S, Thomsen MB, Nielsen RL, Liu D, Wang G, Hou Y, Zhang X, Xu X, Bolund L, Yang H, Wang J, Moreira J, Ditzel HJ, Brünner N, Schrohl AS, Stenvang J, Gupta R. The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. BMC Genomics 2016;17:442. [PMID: 27277198 DOI: 10.1186/s12864-016-2749-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
56 Tanabe Y, Hashimoto K, Shimizu C, Hirakawa A, Harano K, Yunokawa M, Yonemori K, Katsumata N, Tamura K, Ando M, Kinoshita T, Fujiwara Y. Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer. Int J Clin Oncol 2013;18:132-8. [PMID: 22105895 DOI: 10.1007/s10147-011-0352-x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
57 Vici P, Brandi M, Giotta F, Foggi P, Schittulli F, Di Lauro L, Gebbia N, Massidda B, Filippelli G, Giannarelli D, Di Benedetto A, Mottolese M, Colucci G, Lopez M. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study. Ann Oncol 2012;23:1121-9. [PMID: 21965475 DOI: 10.1093/annonc/mdr412] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
58 Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, Jenderek C, Andergassen U, Jeschke U, Friese K. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. J Cancer Res Clin Oncol 2010;136:1029-37. [PMID: 20052594 DOI: 10.1007/s00432-009-0748-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
59 Turner NC, Jones AL. Management of breast cancer--Part II. BMJ 2008;337:a540. [PMID: 18621762 DOI: 10.1136/bmj.a540] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
60 Ribeiro J, Sousa B, Cardoso F. Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment. EJC Suppl 2013;11:3-22. [PMID: 26217109 DOI: 10.1016/j.ejcsup.2013.07.029] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
61 Zhang W, Jiang Z, Wang L, Li C, Xia J. An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy. Med Oncol 2015;32:147. [PMID: 25820754 DOI: 10.1007/s12032-015-0537-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
62 Lee HB, Han W. Unique features of young age breast cancer and its management. J Breast Cancer 2014;17:301-7. [PMID: 25548576 DOI: 10.4048/jbc.2014.17.4.301] [Cited by in Crossref: 48] [Cited by in F6Publishing: 33] [Article Influence: 6.9] [Reference Citation Analysis]
63 Ginés J, Sabater E, Martorell C, Grau M, Monroy M, Casado MA. Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials. Clin Transl Oncol 2011;13:485-98. [PMID: 21775276 DOI: 10.1007/s12094-011-0686-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
64 Gooding AJ, Schiemann WP. Epithelial-Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance. Mol Cancer Res. 2020;18:1257-1270. [PMID: 32503922 DOI: 10.1158/1541-7786.mcr-20-0067] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 24.0] [Reference Citation Analysis]
65 Kim JS, Park IH, Lee KS, Ro J. Outcomes of palliative weekly low-dose gemcitabine-Cisplatin chemotherapy in anthracycline- and taxane- pretreated metastatic breast cancer patients. J Breast Cancer 2014;17:339-43. [PMID: 25548581 DOI: 10.4048/jbc.2014.17.4.339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
66 Kimura K, Tanaka S, Iwamoto M, Fujioka H, Takahashi Y, Sato N, Terasawa R, Tominaga T, Ikari A, Uchiyama K. Safety of nanoparticle albumin-bound paclitaxel administered to breast cancer patients with clinical contraindications to paclitaxel or docetaxel: Four case reports. Oncol Lett 2013;6:881-4. [PMID: 24137430 DOI: 10.3892/ol.2013.1471] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
67 Varna M, Bousquet G, Plassa LF, Bertheau P, Janin A. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol 2011;2011:284584. [PMID: 21760703 DOI: 10.1155/2011/284584] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
68 Recchia F, Candeloro G, Necozione S, Desideri G, Cesta A, Recchia L, Rea S. Vascular endothelial growth factor expression and T-regulatory cells in premenopausal breast cancer. Oncol Lett 2013;5:1117-22. [PMID: 23599749 DOI: 10.3892/ol.2013.1142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
69 de Bessa Garcia SA, Pavanelli AC, Cruz E Melo N, Nagai MA. Prostate apoptosis response 4 (PAR4) expression modulates WNT signaling pathways in MCF7 breast cancer cells: A possible mechanism underlying PAR4-mediated docetaxel chemosensitivity. Int J Mol Med 2017;39:809-18. [PMID: 28259909 DOI: 10.3892/ijmm.2017.2900] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
70 Yu K, Sang QA, Lung PY, Tan W, Lively T, Sheffield C, Bou-Dargham MJ, Liu JS, Zhang J. Personalized chemotherapy selection for breast cancer using gene expression profiles. Sci Rep 2017;7:43294. [PMID: 28256629 DOI: 10.1038/srep43294] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
71 Voidey A, Pivot X, Woronoff AS, Nallet G, Cals L, Schwetterle F, Limat S. Organizing medical oncology care at a regional level and its subsequent impact on the quality of early breast cancer management: a before-after study. BMC Health Serv Res 2014;14:326. [PMID: 25070624 DOI: 10.1186/1472-6963-14-326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV, Bretas FF. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol. 2014;14:9. [PMID: 24460605 DOI: 10.1186/1471-2490-14-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
73 Yamamoto Y, Kawano I, Iwase H. Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval. Onco Targets Ther 2011;4:123-36. [PMID: 21792318 DOI: 10.2147/OTT.S13836] [Cited by in Crossref: 41] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
74 Qin YY, Li H, Guo XJ, Ye XF, Wei X, Zhou YH, Zhang XJ, Wang C, Qian W, Lu J, He J. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients. PLoS One 2011;6:e26946. [PMID: 22069477 DOI: 10.1371/journal.pone.0026946] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 4.0] [Reference Citation Analysis]
75 Nomura H, Aoki D, Michimae H, Mizuno M, Nakai H, Arai M, Sasagawa M, Ushijima K, Sugiyama T, Saito M, Tokunaga H, Matoda M, Nakanishi T, Watanabe Y, Takahashi F, Saito T, Yaegashi N; Japanese Gynecologic Oncology Group. Effect of Taxane Plus Platinum Regimens vs Doxorubicin Plus Cisplatin as Adjuvant Chemotherapy for Endometrial Cancer at a High Risk of Progression: A Randomized Clinical Trial. JAMA Oncol 2019;5:833-40. [PMID: 30896757 DOI: 10.1001/jamaoncol.2019.0001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 17.0] [Reference Citation Analysis]
76 Brouckaert O, Wildiers H, Floris G, Neven P. Update on triple-negative breast cancer: prognosis and management strategies. Int J Womens Health 2012;4:511-20. [PMID: 23071421 DOI: 10.2147/IJWH.S18541] [Cited by in Crossref: 17] [Cited by in F6Publishing: 47] [Article Influence: 1.9] [Reference Citation Analysis]
77 Dörfel S, Steffens CC, Meyer D, Tesch H, Kruggel L, Frank M, Jänicke M, Marschner N; TMK-Group (Tumour Registry Breast Cancer). Adjuvant chemotherapeutic treatment of 1650 patients with early breast cancer in routine care in Germany: data from the prospective TMK cohort study. Breast Cancer 2018;25:275-83. [PMID: 29204847 DOI: 10.1007/s12282-017-0823-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 McGuire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev 2015;34:145-55. [PMID: 25721950 DOI: 10.1007/s10555-015-9551-7] [Cited by in Crossref: 155] [Cited by in F6Publishing: 141] [Article Influence: 31.0] [Reference Citation Analysis]
79 Tengström M, Mannermaa A, Kosma VM, Hirvonen A, Kataja V. SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer? BMC Cancer 2012;12:257. [PMID: 22708928 DOI: 10.1186/1471-2407-12-257] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
80 Ellis P, Barrett-Lee P, Johnson L, Cameron D, Wardley A, O'Reilly S, Verrill M, Smith I, Yarnold J, Coleman R, Earl H, Canney P, Twelves C, Poole C, Bloomfield D, Hopwood P, Johnston S, Dowsett M, Bartlett JM, Ellis I, Peckitt C, Hall E, Bliss JM; TACT Trial Management Group., TACT Trialists. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. Lancet 2009;373:1681-92. [PMID: 19447249 DOI: 10.1016/S0140-6736(09)60740-6] [Cited by in Crossref: 133] [Cited by in F6Publishing: 43] [Article Influence: 11.1] [Reference Citation Analysis]
81 Lovat F, Ishii H, Schiappacassi M, Fassan M, Barbareschi M, Galligioni E, Gasparini P, Baldassarre G, Croce CM, Vecchione A. LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer. Oncotarget. 2014;5:970-977. [PMID: 24448468 DOI: 10.18632/oncotarget.1630] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
82 López-Tarruella S, Martín M. Recent advances in systemic therapy: advances in adjuvant systemic chemotherapy of early breast cancer. Breast Cancer Res 2009;11:204. [PMID: 19344489 DOI: 10.1186/bcr2226] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
83 Younus J, Vandenberg T, Jawaid M, Jawaid MA. Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-an updated analysis. Curr Oncol 2012;19:332-4. [PMID: 23300360 DOI: 10.3747/co.19.1174] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
84 Kim SW, Choi DH, Huh SJ, Park W, Nam SJ, Kim SW, Lee JE, Im YH, Ahn JS, Park YH. Lymph Node Ratio as a Risk Factor for Locoregional Recurrence in Breast Cancer Patients with 10 or More Axillary Nodes. J Breast Cancer 2016;19:169-75. [PMID: 27382393 DOI: 10.4048/jbc.2016.19.2.169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
85 Palmieri C, Krell J, James CR, Harper-Wynne C, Misra V, Cleator S, Miles D. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat Rev Clin Oncol. 2010;7:561-574. [PMID: 20808300 DOI: 10.1038/nrclinonc.2010.122] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]